Biophytis H1 EPS $(0.08) Up From $(0.17) YoY

Biophytis (NASDAQ:BPTS) reported quarterly losses of $(0.08) per share. This is a 52.94 percent increase over losses of $(0.17) per share from the same period last year.

byBenzinga Newsdesk

January 31, 2023

1 minute read

Biophytis (NASDAQ:BPTS) reported quarterly losses of $(0.08) per share. This is a 52.94 percent increase over losses of $(0.17) per share from the same period last year.

Fate Therapeutics Announces Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma

By Michael Horton

Today, 1:24 AM

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today highlighted positive interim clinical data from the

FATE

FDA Rejects Supernus Pharma’s Minimally Invasive Parkinson’s Therapy

By Vandana Singh

Today, 1:24 AM

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) received FDA’s complete response letter (CRL) for the SPN-830 marketing application. SPN-830 is an investigational apomorphine infusion…

SUPN

MindMed Leverages Ayahuasca’s Ingredient DMT In Psychedelic-Inspired Therapies, Launches Trials With 30 Subjects

By Jelena Martinovic

Today, 1:24 AM

Psychoactive brew ayahuasca is known for having a fast-onset antidepressant effect. With serotonergic psychedelics, such as ayahuasca, giving promising results in the quest for alternative treatments for depression and anxiety, many companies are turning their focus to developing psychedelic-inspired therapies.

MNMD